Pfizer, pocketing a big tax cut from Trump, ends investment in Alzheimer’s and Parkinson’s research.

Mar 28, 2018

By Nurse Talk

With every passing day, it becomes clearer who’s reaping the benefit of the huge tax cut handed over to American corporations by the Republican-dominated Congress in December. The big drug company Pfizer seems intent on being a pace-setter in cranking out the benefits of the tax cut to stakeholders who need them the least. In an announcement in late January, Pfizer said it was shutting down its research efforts on treatments for Alzheimer’s and Parkinsonism. The company didn’t say how much it was spending on the two conditions, but said about 300 researchers will lose their jobs as it redirects its research and development budget elsewhere. Healthcare In America’s Donna Smith talks about what this means to those who count on continued research.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

SIGN THE OPEN LETTER!

Sign the Open Letter to the DNC demanding a Democratic Debate on the Climate Emergency!

Poverty, Hunger & Housing

Please join us in calling on the Democratic National Committee and the News Networks hosting televised Democratic Party primary debates to prioritize questions on the crisis of poverty, housing, and hunger in the United States; and to ensure that the voices and concerns of the poorest Americans are being heard at this critically important moment for our democracy.

Sign the Petition!